The direct-to-patient (DTP) market is full of providers making bold claims. But claims are not outcomes. To unlock the true potential of DTP, manufacturers should stop asking: ‘What does your platform do?’ and start asking: ‘What does your platform prove?’
The answer comes from three core pillars: commercial outcomes, patient outcomes and platform outcomes. When a DTP program is working, it will deliver proven results across all three pillars consistently and at scale. Because in specialty pharma, the gap between breakthrough therapy and the patient it was built for isn’t usually the science. It’s a journey problem.
Commercial Outcomes
A high-performing DTP program should deliver measurable results across key commercial areas including real-time visibility that enables proactive intervention, faster time to first fill and reduced abandonment. For too long, delays in prescription fill have eroded patient trust and increased drop-off, impacting the bottom line for manufacturers.
In contrast, rapid, predictable prescription fulfillment can help to build brand loyalty from day one and deliver measurable ROI. Gifthealth has reduced the average time-to-fill for DTP cash programs, when compared to the national average with similar observations across dispense rates for approved medications. Manufacturers launching or defending a brand-name medication in a crowded market need patients to start therapy without delay. Gifthealth’s extensive pharmacy network is built to shorten fill times and remove barriers to access. Combined with improved patient affordability and fewer physician callbacks through automation and education, this approach is designed to help brand-name medications compete in a generic-dominated market.
Patient Outcomes
Nothing should stand in the way of better health. But under the current system, too many patients are missing out on new treatments. Even a well executed product launch still fails most of the patients it was built for. Research shows that between 60-70% of patients prescribed specialty medications never start or discontinue treatment within the first few months, with friction points across the patient journey the leading cause. While existing support services are designed to stop patients falling away, they are often underused, or unseen, by those who need them most.
When choosing a DTP partner, manufacturers should look for the following quantifiable patient outcomes: fewer handoffs, faster time to first fill, higher persistence on therapy, and higher satisfaction. This requires not just technological solutions or human support but a tech-plus-touch approach which combines the best of both, meets patients where they are, and helps overcome common challenges.
Across 11 million patient journeys year to date (as of October 2026), Gifthealth has maintained customer satisfaction scores above 90%. Patients who feel supported stay engaged, and Gifthealthconsistently sees persistence rates meaningfully higher than the national average.This isn’t a pilot result, it’s how the model performs everyday.
Platform Outcomes
The DTP space includes a number of platforms that offer integration. But there’s a difference between a platform that’s been stitched together and one that’s been built from the ground up to own the full journey. Specialty pharma programs have traditionally relied on separate vendors for each stage of the prescription journey — diagnosis support, specialist access, prior authorization, dispensing, patient support, and adherence.
A truly integrated single-partner platform inverts that math. One partner owns the prescription journey from intake through delivery and adherence. If each vendor in a six-vendor model converted 80% of patients at their stage, you would quietly lose three-quarters of your eligible patients. That wouldn’t be six vendors underperforming. It would be the model performing exactly as designed. Nobody owns the sum of the requirements.
Every handoff eliminated reduces the chance of patient drop-off, keeping more patients moving through the funnel toward first fill and beyond. Manufacturers should look for one data feed, one contract, and one point of accountability. Not a vendor that’s dressed up fragmentation as a unified solution.
Proof Over Promise
In a crowded DTP market where integration and real-time visibility is widely offered by vendors, proof points – not positioning – are what differentiate. The vendor-stack model doesn’t fail because individual partners underperform. It fails because nobody owns the sum of the requirements. Commercial outcomes, patient outcomes, and platform outcomes don’t live in three separate systems. They sink or swim together, in one journey, with one accountable owner.
Manufacturers who understand that distinction won’t just find a better vendor. They’ll build a fundamentally different kind of program, one where the journey carries the patient, instead of the patient carrying the journey.